


FastSeal™ Bioabsorbable Vascular Access Closure System

Russ Houser, CEO¹, Alessandro Bortone, MD, PhD, FESC²

¹ Vascular Closure Systems, Inc, Livermore, USA, ² Institute of Cardiac Surgery, Interventional Laboratory, University of Bari, Bari, Italia

First In Man (FIM) clinical evaluation testing will soon be conducted using the FastSeal™ Bioabsorbable Vascular Access Closure System. The system has only two components - a delivery capsule (with the absorbable plug pre-loaded) and an advancement plunger. The closure plug element is fabricated from an absorbable polymer blend, and is designed to leave nothing within the vessel after less than two weeks, and is completely absorbed within 60 days. After the interventional procedure has been completed (and the catheter has been withdrawn) the capsule, containing the plug element, is inserted through the proximal hub valve of the same procedural sheath (the system can be used with any commercially available vascular introducer sheath). The plunger is then inserted into the back of the capsule, engaging and advancing the plug forward (through the introducer sheath) until the plunger thumb rest is up against the back of the capsule, partially deploying the plug past the end of the introducer sheath and into the vessel. The sheath and the plunger are then withdrawn together from the body, fully deploying the plug, and providing acute hemostasis of the puncture site. The advancement and deployment of the plug takes a total of less than 10 seconds. When commercialized, the target sales price for the system will be less than \$150. per set - even with a sales price as low as \$100., the company will still be able to realize typical medical device margins (70% to 80%), while pricing our system at least 50% less than other competitive systems.



Vascular Closure Systems, Inc. (www.vclosure.com) is a privately held medical device company, based in part on the established intellectual property of CardioVascular Technologies, Inc. (www.cvtechinc.com), and is focused on the development and commercialization of the optimal vascular access closure system for the Interventional Cardiology market. The company is comprised of several seasoned medical device professionals and world class physicians, with a proven record of innovation, clinical acumen, and successful commercialization of multiple medical device technologies. The company is currently raising funds (third round) to support product and IP development, regulatory and commercialization activities.

The company's vascular access closure technologies are covered by more than thirteen issued and pending patents.